首页> 外文期刊>Saudi Pharmaceutical Journal >Synthesis and evaluation of a pyrazinoic acid prodrug in Mycobacterium tuberculosis
【24h】

Synthesis and evaluation of a pyrazinoic acid prodrug in Mycobacterium tuberculosis

机译:结核分枝杆菌中吡嗪酸前药的合成与评价

获取原文
           

摘要

Tuberculosis (TB) is a disease caused mainly by infection of Mycobacterium tuberculosis affecting more than ten million people around the world. Despite TB can be treated, the rise of MDR-TB and XDR-TB cases put the disease in a worrying status. As pyrazinamide-resistant strains exhibit low or none pyrazinamidase activity, it is proposed that the active form of pyrazinamide (PZA) is pyrazinoic acid (POA), although this acid has poor penetration in mycobacteria. In this work, we present a convenient one-pot synthesis of 2-chloroethyl pyrazinoate, and its activity in M. tuberculosis H"3"7Rv (ATCC27294) in MIC assay using the MABA technique. The obtained MIC of the compound was 3.96g/mL, and discussion about the activity profile of some previously evaluated pyrazinoates is also performed.
机译:结核病(TB)是一种主要由结核分枝杆菌感染引起的疾病,感染了全球超过一千万的人。尽管可以治疗结核病,但耐多药结核病和广泛耐药结核病病例的增加使该病处于令人担忧的状态。由于吡嗪酰胺抗性菌株表现出低的吡嗪酰胺酶活性或没有吡嗪酰胺酶活性,因此提出吡嗪酰胺(PZA)的活性形式为吡嗪酸(POA),尽管该酸在分枝杆菌中的渗透性较差。在这项工作中,我们提出了一种方便的一锅合成吡嗪二酸二氯乙酯,及其在使用MABA技术的MIC分析中在结核分枝杆菌H“ 3” 7Rv(ATCC27294)中的活性。所获得的化合物的MIC为3.96g / mL,并且还进行了关于一些先前评价的吡嗪酸酯的活性谱的讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号